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Abstract
Background:  Oxidative stress is involved in cisplatin-nephrotoxicity. However, it has not
completely established if reactive nitrogen species and nitrosative stress are involved in this
experimental model. The purpose of this work was to study the role of peroxynitrite, a reactive
nitrogen specie, in cisplatin-nephrotoxicity using the compound 5,10,15,20-tetrakis (4-
sulfonatophenyl) porphyrinato iron (III) (FeTPPS), a soluble complex able to metabolize
peroxynitrite.
Results: In rats treated with cisplatin (a single intraperitoneal dose of 7.5 mg/kg body weight), renal
nitrosative stress was made evident by the increase in 3-nitrotyrosine on day 3. In addition,
cisplatin-induced nephrotoxicity was evident by the histological damage of proximal tubular cells
and by the increase in (a) serum creatinine, (b) blood urea nitrogen, and (c) urinary excretion of
N-acetyl-β-D-glucosaminidase and total protein. Cisplatin-induced nitrosative stress and
nephrotoxicity were attenuated by FeTPPS-treatment (15 mg/kg body weight, intraperitoneally,
every 12 hours for 3 days).
Conclusions: Nitrosative stress is involved in cisplatin-induced nephrotoxicity in rats. Our data
suggest that peroxynitrite is involved, at least in part, in cisplatin-induced nephrotoxicity and
protein nitration.
Background
Cisplatin (cis-dichlorodiammine-platinum II) is an effec-
tive antineoplastic agent in the treatment of various solid
tumours [1] including cancers of the ovary, testis, bladder,
head, neck, lung, cervix, and endometrium [2]. Neverthe-
less, its full clinical utility is limited due to some adverse
side effects including acute renal failure. The major site of
renal injury is the S3 segment of the proximal tubule,
located in the outer stripe of the outer medulla of the kid-
ney [1]. The production of reactive oxygen species (ROS)
and oxidative stress in kidney have been implicated in the
pathogenesis of cisplatin-induced renal injury [3]. It has
been shown that superoxide anion (O2
•-) [4], hydrogen
peroxide (H2O2) [5], and hydroxyl radical (•OH) [6] are
involved in cisplatin-induced nephrotoxicity. In addition,
it has been found that renal lipid peroxidation [5,7] is
increased and glutathione is decreased [8] in this experi-
mental model. The involvement of oxidative stress is fur-
ther supported by the fact that the antioxidants melatonin
[9] and vitamins C and E [5,10] prevent cisplatin-induced
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nephrotoxicity. Interestingly, overexpression of heme oxy-
genase-1 ameliorates [11] and heme oxygenase-1 defi-
ciency [12] aggravates renal damage induced by cisplatin,
supporting additionally the involvement of oxidant stress
in this experimental model.
On the other hand, the role of reactive nitrogen species
(RNS) and nitrosative stress has been less explored in cis-
platin-induced nephrotoxicity. In this context, it has been
studied the role of nitric oxide (•NO) and nitric oxide syn-
thase (NOS) [13-19]. It has been found that the renal con-
tent of total nitrate/nitrite is increased in cisplatin-treated
rats [18,19] suggesting that •NO production is enhanced
in these animals. Furthermore, the inhibition of NOS by
L-NAME [14] or by aminoguanidine [13] decreased renal
damage induced by cisplatin, suggesting that •NO is play-
ing a toxic role in this experimental model. However, it is
unknown if peroxynitrite (ONOO-), a RNS that is gener-
ated by the reaction of •NO and O2
•-, is involved in the
renal damage induced by cisplatin. It has been shown that
ONOO-, which is not a free radical, is involved in the
pathogenesis of many diseases [20-25]. ONOO- can react
with different biomolecules including amino acids such
as cysteine, methionine, tryptophan, and tyrosine leading
to changes in protein structure and function [26]. ONOO-
has been shown to cause lipid peroxidation, chemical
cleavage of DNA, and reduction in cellular defenses by
oxidation of thiol pools [27].
In this work, we studied if ONOO- is involved in the neph-
rotoxicity induced by cisplatin by using 5,10,15,20-tet-
rakis (4-sulfonatophenyl) porphyrinato iron (III)
(FeTPPS). This compound is a water-soluble Fe (III) por-
phyrin complex that catalyzes rapid isomerization of
ONOO- to nitrate (NO3
-) under physiologically relevant
conditions (pH 7.4, 37°C) [28]. The cytoprotective
actions of FeTPPS have been characterized [29].
Results
Body weight and urinary volume
Body weight decreased 8.5% in cisplatin (Cis) group on
day 3 and FeTPPS tended to prevent this decrease in
Cis+FeTPPS group, however there was no significative dif-
ference between Cis and Cis+FeTPPS groups. Body weight
was similar in control (Ct), FeTPPS, and Cis+FeTPPS
groups. Urinary volume was not significative difference
among the four groups along the study and on day of sac-
rifice (Table 1).
Markers of glomerular and tubular damage
Serum creatinine increased 4.9 times and blood urea
nitrogen (BUN) increased 5.5 times in Cis group com-
pared to control one (Fig 1). FeTPPS prevented partially
the increase in serum creatinine and BUN levels in
Cis+FeTPPS group. Cisplatin increased urinary excretion
of total protein (4.6 times) and N-acetyl-β-D-glucosamin-
idase (NAG) (9.6 times) (Fig 2A and 2B). The increase in
both parameters was prevented by FeTPPS in Cis+FeTPPS
group (Fig 2). Serum creatinine, BUN, and urinary excre-
tion of total protein and NAG were similar in Ct and
FeTPPS groups (Figs 1 and 2).
Histological analysis
After three days of cisplatin-treatment, the epithelium
from proximal convoluted tubules (tubules with small
lumen area and taller epithelial cells) showed cytoplasmic
vacuolization, intracellular edema and extensive damage
which affected 87 ± 4% of their surface area (Fig 3B). The
cisplatin toxic activity was higher in the straight portion of
proximal convoluted tubules located in the inner area of
the kidney cortex, where more than 90% of the epithelial
surface suffered damage (Fig 4B). Interestingly, FeTPPS
administration partially decreased the damaged area from
87 ± 4 to 44 ± 6% (p < 0.0001) in proximal convoluted
tubules (Fig 3D) and from 93 ± 2 to 68 ± 10 (p < 0.0001)
in the straight portion (Fig 4D). The administration of
FeTPPS did not produce any histological alteration in the
kidneys (Figs 3C and 4C). At the light microscopy level,
glomeruli structure remained unchanged in all groups.
Immunohistochemical localization of 3-nitro-L-tyrosine (3-
NT)
A strong 3-NT immunostaining was observed in the
straight portion of the proximal convoluted tubules
located in the inner area of the kidney cortex of cisplatin-
treated rats (Fig 5B). Interestingly, in the Cis+FeTPPS
group, FeTPPS administration partially prevented the
cisplatin toxic damage in the epithelium from the proxi-
mal convoluted tubules and its straight portion respec-
tively, in coexistence with an evident decrease of 3-NT
immunostaining (Fig 5D).
Discussion
Cisplatin in an effective chemotherapeutic agent for a
wide variety of tumors, nevertheless, nephrotoxicity is the
major complication of this antineoplasic treatment [1].
The mechanism by which cisplatin causes renal damage is
unclear, however, it has been postulated that oxidative
Table 1: Body weight and urinary volume in the 4 groups of rats 
studied on day 3.
Ct Cis FeTPPS Cis+ FeTPPS
Body weight (g) 235 ± 5a 215 ± 4b 238 ± 3a 231 ± 4a
Urinary volume 
(mL/24 h)
5.7 ± 1.4a 7.4 ± 0.8a 3.5 ± 1.1a 7.4 ± 1.6a
Values are mean ± SEM. n = 6. Groups with different letter are 
significantly different (P < 0.05).BMC Pharmacology 2004, 4:20 http://www.biomedcentral.com/1471-2210/4/20
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stress is involved in this process [2,3,13,30]. The protec-
tive effect of overexpression of Mn-SOD [4] or the in vivo
administration of some antioxidants such as vitamins C
and E [5,10], melatonin [9], or selenium [31] in cisplatin-
induced nephrotoxicity as well as the protective effect of
tiron (a cell permeable O2
•-  scavenger), pyruvate and
catalase (H2O2  scavengers), and dimethylthiourea and
thiourea (•OH scavengers) in renal proximal tubular epi-
thelial cells (LLC-PK1 cells) treated with cisplatin also
strongly support the role of ROS in cisplatin renal toxicity
[30].
In contrast the role of •NO and RNS in cisplatin-induced
nephrotoxicity has not been completely established. It has
been shown that the renal content of nitrate/nitrite is
increased in cisplatin-treated rats suggesting that •NO is
increased in these animals [18,19]. In fact it has been
shown that renal NOS activity is increased in cisplatin-
treated rats [14]. In addition, the following two experi-
ments suggest a toxic role of •NO on cisplatin-induced
renal toxicity: (a) aminoguanidine, an inhibitor of induc-
ible NOS, decreased nephrotoxicity and prevented kidney
lipid peroxidation and reduction of antioxidant enzymes
induced by cisplatin [13], and (b) the administration of
N(G)-nitro-L-arginine methyl ester (L-NAME), an inhibi-
tor of NOS, reduced renal and gastrointestinal toxicity
along with a significant inhibition in lipid peroxidation
(A) Serum creatinine and (B) BUN on day 3 in the four  groups of rats studied Figure 1
(A) Serum creatinine and (B) BUN on day 3 in the four 
groups of rats studied. Ct: control group, Cis: cisplatin group; 
FeTPPS: 5,10,15,20-tetrakis(4-sulfonatophenyl) porphyrinato 
iron (III) group, and Cis+FeTPPS: cisplatin+5,10,15,20-tet-
rakis(4'-sulfonatophenyl) porphyrinato iron (III) group. Data 
are mean ± SEM. n = 6. aP < 0.001 vs. Ct; bP < 0.001 vs. Ct, 
cP < 0.05 vs Cis (Panel A); aP < 0.001 vs. Ct; bP < 0.001 vs. 
Ct, cP < 0.001 vs Cis (Panel B). Serum creatinine and BUN 
increased in cisplatin group and FeTPPS prevented these 
increases in the Cis+FeTPPS group.
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Urinary excretion of (A) total protein and (B) NAG on day 3  in the four groups of rats studied Figure 2
Urinary excretion of (A) total protein and (B) NAG on day 3 
in the four groups of rats studied. Data are mean ± SEM. n = 
5–6. aP < 0.001 vs. Ct, bP < 0.05 vs. Cis. Cisplatin-treated rats 
increased urinary excretion of total protein and NAG and 
these increases were prevented by FeTPPS administration in 
Cis+FeTPPS group.
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Representative histological abnormalities in the external cortical kidney area after three days of cisplatin administration and  their partial prevention by FeTPPS Figure 3
Representative histological abnormalities in the external cortical kidney area after three days of cisplatin administration and 
their partial prevention by FeTPPS. (A) Normal kidney histology from control rat. (B) After three days of cisplatin administra-
tion, many cortical convoluted tubules are revisted by necrotic epithelial cells (arrows) or vacuolated swell cells (arrow heads), 
glomeruli do not show apparent damage. (C) FeTPPS administration does not produce histological kidney abnormalities. (D) 
The administration of FeTPPS partially prevents the cytotoxic damage induced by cisplatin; arrows indicate middle cellular vac-
uolization of cortical convoluted tubules.
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Representative histological abnormalities in the inner part of the cortical kidney after three days of cisplatin administration and  their partial prevention by FeTPPS Figure 4
Representative histological abnormalities in the inner part of the cortical kidney after three days of cisplatin administration and 
their partial prevention by FeTPPS. (A) Normal kidney histology from control rat. (B) After three days of cisplatin administra-
tion, the straight portion of many cortical tubules are revisted by necrotic cells (arrows). (C) FeTPPS administration does not 
produce histological abnormalities. (D) The administration of FeTPPS partially prevents the cytotoxic damage induced by cispl-
atin; arrows indicate tubules with focal necrotic cells.
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Nitrotyrosine (3-NT) expression determined by immunohistochemistry in the inner part of the cortical kidney after three days  of cisplatin administration and its partial prevention by FeTPPS Figure 5
Nitrotyrosine (3-NT) expression determined by immunohistochemistry in the inner part of the cortical kidney after three days 
of cisplatin administration and its partial prevention by FeTPPS. (A) There is no 3-NT immunostaining in the kidney of control 
rat. (B) In contrast, three days after cisplatin administration there is a strong 3-NT expression in the necrotic cells from the 
straight portion of the proximal convoluted tubules (arrows). (C) FeTPPS administration does not induce 3-NT expression. 
(D) The administration of FeTPPS strongly decreases 3-NT expression induced by cisplatin-treatment (Cis+FeTPPS group).
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induced by cisplatin [14]. In contrast, Mansour et al. [15]
and Li et al. [16] have found that L-NAME administration
resulted in no protection and Saad et al. [17] found that
this NOS inhibitor aggravates cisplatin-induced renal dys-
function. These data may suggest that •NO is not playing
a toxic role in cisplatin-induced nephrotoxicity. The above
mentioned disagreement justify the performance of addi-
tional experiments to clarify the role of NOS and •NO in
cisplatin-induced nephrotoxicity.
On the other hand, •NO is able to react with O2 
•- to pro-
duce ONOO-, which is a powerful oxidant more, reactive
than its precursors, and has been implicated in an increas-
ing list of diseases: hyperlipidemia [32], Alzheimer [20],
acute renal ischemia [25], neurotoxicity induced by meth-
amphetamine [33], and diabetes [23]. The ONOO-
decomposition catalyst FeTPPS is a water-soluble Fe (III)
porphyrin complex able to block ONOO- toxicity [28,29]
and to protect against toxic insults in several experimental
models. In focal cerebral ischemia-reperfusion in rats,
massive production of •NO and O2
•- results in continuous
formation of ONOO- even several hours after ischemia-
reperfusion insult [34]. Significant reduction of 3-NT in
brain sections and prominent neuroprotection was
observed by FeTPPS (30 mg/kg) [34]. In a model of sepsis
induced by injection of endotoxin (10 mg/kg) in rats,
FeTPPS prevented the accumulation of ONOO- as meas-
ured by plasma rhodamine fluorescence and heart 3-NT
staining [35]. Interestingly, FeTPPS improved endotoxin-
induced myocardial contractile dysfunction, which was
associated with reduced degradation of nuclear factor
kappa B inhibitory protein I-kappa-B, plasma TNF-alpha
levels, and microvascular endothelial cell-leukocyte acti-
vation [35].
In this work it was found that FeTPPS partially prevented
the increase in BUN and serum creatinine (markers of
glomerular damage) and urinary excretion of NAG and
total protein (markers of tubular damage) induced by cis-
platin-treatment. The increase in urinary NAG and total
protein excretion could be associated with necrosis of the
proximal convoluted tubules, the primary site of drug
accumulation [1]. FeTPPS prevented these alterations
induced by cisplatin. This may be secondary to the ability
of FeTPPS to catalyze the decomposition of ONOO- which
could be responsible, at least in part, of the alterations
induced by cisplatin. This ameliorative effect of FeTPPS
was associated with the decrease in 3-NT staining suggest-
ing that ONOO- is involved in protein nitration in cispla-
tin-nephrotoxicity. It is known that another RNS such as
N2O4, HONOO, •NO2 [36], and nitryl chloride (NO2Cl)
[37], are involved in protein nitration. Nitryl chloride is
formed by the reaction of NO2
- and HOCl-derived mye-
loperoxidase [37].
Studies in animals have established that tubular injury
plays a central role in the reduction of glomerular
filtration rate in acute tubular necrosis. Two major tubular
abnormalities could be involved in the decrease in
glomerular fucntion in cisplatin-treated rats: obstruction
and backleak of glomerular filtrate. The alteration in
glomerular function can not be attributed to structural
damage since glomeruli structure is normal in cisplatin-
treated rats. The alterations in glomerular function in cis-
platin-treated rats may also be secondary to ROS [38]
which induce mesangial cells contraction, altering the fil-
tration surface area and modifying the ultrafiltration coef-
ficient, factors that decrease the glomerular filtration rate.
In addition our data suggest that ONOO- may also be
involved in the glomerular alterations in cisplatin-treated
rats.
The increase in renal ONOO- induced by cisplatin may be
secondary to the increase in •NO and O2
•- production. In
fact, there are evidences of the renal increase in •NO pro-
duction in cisplatin nephrotoxicity [18,19] and O2
•- gen-
eration in cisplatin-treated LLC-PK1 cells [30]. The O2
•-
increase in cisplatin-nephrotoxicity may be simply conse-
quence of the mitochondrial dysfunction [39] and the
decrease in superoxide dismutase activity [5].
Conclusions
Nitrosative stress is involved in cisplatin-induced nephro-
toxicity in rats. The ameliorative effect of FeTPPS on
cisplatin-induced nephrotoxicity in rats was associated
with the decrease in protein nitration suggesting that
ONOO- is involved in both protein nitration and nephro-
toxicity in these animals.
Methods
Reagents
Cisplatin (catalogue # P-4394) was from Sigma-Aldrich
(St. Louis MO, USA). FeTPPS (catalogue # 341492) was
from (Calbiochem, San Diego, CA, USA). Rabbit anti-3-
NT polyclonal antibodies (Catalogue # 06–284) were
from Upstate (Lake Placid, NY, USA). Anti-rabbit Ig horse-
radish peroxidase antibodies (Catalogue # SAB-300) were
purchased from Stressgen (Victoria BC, Canada). Com-
mercial kits to measure creatinine and urea were from
Spinreact (Girona, Spain). All other chemicals were rea-
gent grade and commercially available.
Experimental design
Male Wistar rats (Harlan Teklad, Mexico City, Mexico) ini-
tially weighing 200–250 g were used. Experimental work
was approved by DGAPA (IN227103) and followed the
guidelines of Norma Oficial Mexicana (NOM-ECOL-087-
1995). All animals had free access to water and commer-
cial rodent diet (Harlan Teklad, catalogue 2018S), and
were randomly divided in four groups (n = 6 rats/group)BMC Pharmacology 2004, 4:20 http://www.biomedcentral.com/1471-2210/4/20
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as follows: (1) CT, injected intraperitoneally (i.p.) with
isotonic saline solution; (2) Cis, treated with a single dose
of cisplatin (7.5 mg/Kg b.w./i.p.) [40]; (3) FeTPPS, treated
with FeTPPS (15 mg/kg/i.p./12 h) [32] for 3 days; and (4)
Cis+FeTPPS, treated with Cis and with FeTPPS. During the
study rats were maintained with a 12-h light:dark cycle in
stainless steel metabolic cages to collect urine. On day 3,
the animals were sacrificed by decapitation and blood was
collected to obtain serum and to measure creatinine and
BUN. Total protein and NAG were measured in 24-h
urine. The kidneys were removed to obtain cortex samples
for histological and immunohistochemical studies.
Markers of glomerular and tubular damage
The markers of glomerular damage, creatinine and urea,
were measured using commercial kits. BUN was obtained
by correcting the urea value by a 2.14 factor [41]. As mark-
ers of tubular damage, we measured urinary excretion of
NAG and total protein. NAG activity was measured using
p-nitrophenyl-N-acetyl-β-D-glucosaminide as substrate
and total protein was measured by a turbidimetric
method [42].
Histological analysis
Thin slices of kidney tissue with cortex and medulla were
fixed by immersion in buffered formalin (pH 7.4), dehy-
drated and embedded in paraffin [43]. Sections of 3 µm
were stained with hematoxilin and eosin. The histological
profile of twenty proximal tubules randomly selected per
rat (6 rats per experimental group) was recorded using a
Leica Qwin Image Analyzer (Cambridge, England). The
percentage of tubular area with histopathological altera-
tions like swelling, cytoplasmic vacuolization, desquama-
tion or necrosis was obtained. The percentage of damaged
area of Cis and Cis+FeTPPS groups was compared.
Immunohistochemical localization of 3-nitro-L-tyrosine (3-
NT)
For immunohistochemistry, 3 µm sections were deparaff-
ined with xylol and rehydrated with ethanol. Endogenous
peroxidase was quenched/inhibited with 4.5% H2O2 in
methanol by incubation for 1.5 h at room temperature.
Nonspecific adsorption was minimized by leaving the sec-
tions in 3% bovine serum albumin in phosphate buffer
saline for 30 min. Sections were incubated overnight with
a 1:700 dilution of anti-3-NT antibody. After extensive
washing with phosphate buffer saline, the sections were
incubated with a 1:1000 dilution of a peroxidase conju-
gated anti-rabbit Ig antibody for 1 h, and finally incubated
with hydrogen peroxide-diaminobenzidine for 10 s. Sec-
tions were counterstained with hematoxilin and observed
under light microscopy. All the sections from the four
studied groups were incubated under the same conditions
with the same antibodies concentration, and in the same
running, so the immunostaining was comparable among
the different experimental groups [43].
Statistics
Results are expressed as the mean ± SEM. Data were ana-
lyzed by one-way ANOVA followed by Bonferroni's mul-
tiple comparisons. Non-paired t-test was used to compare
the quantitative histological damage data using the soft-
ware Prism 3.02 (GraphPad, San Diego, CA, USA). P ≤
0.05 was considered statistically significant.
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